Malignant Gliomas Clinical Trial
Malignant gliomas are aggressive tumours with poor prognosis despite the current multimodal
treatment. Hence, there is a clear need for new, effective therapies, among which immune
therapy has emerged as a promising treatment option.
When interpreting follow-up magnetic resonance (MR) examinations, the radiologist is often
confronted with images that are difficult to interpret with the conventional anatomical
imaging techniques. The difference between tumour relapse and therapy-mediated changes is
not always distinctive.
In this project, the investigators attempt to characterize the inflammatory response with
parameters from advanced MRI techniques like MR spectroscopy, MR perfusion imaging and
MR-diffusion imaging. These techniques allow characterization of cellular properties like
metabolism and tissue structure respectively. Doing so, the investigators will monitor
disease evolution in order to timely detect treatment failure, thereby allowing appropriate
switch in patient management.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03212742 -
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00165477 -
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
| Completed |
NCT02632370 -
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
|
||
| Completed |
NCT02155452 -
Fluorescence and Glioma Heterogeneity
|
||
| Completed |
NCT00590954 -
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
|
Phase 2 | |
| Completed |
NCT00822887 -
Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas
|
Phase 1 | |
| Terminated |
NCT00923117 -
Sunitinib to Treat Recurrent Brain Cancer
|
Phase 2 | |
| Completed |
NCT02731521 -
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
|
||
| Completed |
NCT02388659 -
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
|
||
| Terminated |
NCT01549392 -
Imaging Study of Glioblastomas Treated With Avastin
|
N/A | |
| Completed |
NCT00272350 -
ZD6474 to Treat Advanced Brain Cancer in Patients
|
Phase 1 | |
| Completed |
NCT00271609 -
Bevacizumab for Recurrent Malignant Glioma
|
Phase 2 | |
| Completed |
NCT00074646 -
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
|
Phase 1 | |
| Recruiting |
NCT01670890 -
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
|
Phase 2 | |
| Completed |
NCT00704080 -
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
|
Phase 1 | |
| Completed |
NCT00463073 -
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
|
Phase 2 | |
| Terminated |
NCT00671801 -
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
|
Phase 1 | |
| Withdrawn |
NCT02369367 -
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II)
|
Phase 2 |